Analyst Consensus ?
ConsensusBuy12 ratings
Bullish12100.0%
Neutral00.0%
Bearish00.0%
American Healthcare REIT, Inc. · AHR · FY2026 Q3 · Calendar Q4 2026
AHR raises 2026 outlook as senior-housing NOI growth continues
AHR's Q3 results support a growth case built on operating momentum and external expansion: same-store NOI growth continued and management raised full-year NFFO guidance. The case still depends on sustaining cost control and occupancy and executing acquisitions without weakening capital discipline.
Why did AHR rise 3.3% after missing EPS estimates in FY2026 Q3?
Research this report with FN2. Free to start; review your question before sending.
Reported After market closeNYSEReal Estate
$12.60B market cap
100quality score
Earnings scorecard
Reported versus consensus
Reported EPS
$0.14
Consensus $0.15
EPS surprise
-9.0%
Reported versus consensus
Reported revenue
$742.1M
Consensus $703.5M
Revenue surprise
+5.5%
Reported versus consensus
Market reaction
event-close to next-session close
Stock move
+3.3%
Event window
SPY move
+0.3%
Same window
Abnormal move
+3.0%
Stock minus SPY
Volume
2.0×
Versus trailing sessions
Subsequent drift
0.0%
Up to 20 sessions
AHRSPY benchmark
Ask FN2 about AHR FY2026 Q3
Choose a question to continue your research
Why did AHR rise 3.3% after missing EPS estimates in FY2026 Q3?What changed in AHR's guidance and outlook in FY2026 Q3?Give me the bull and bear case for AHR after FY2026 Q3 earnings.
Free to start. Your question opens in chat for you to review and send. FN2 can look up the transcript, financials and prior quarters.
Transcript intelligence
What changed
Compared with Q2, AHR reported another quarter of double-digit same-store NOI growth and raised full-year NFFO guidance again, to $2.23–$2.26 per share. The company also reported $2.1 billion of year-to-date completed acquisitions and a $1 billion-plus pipeline. Revenue exceeded consensus, while EPS was below consensus.
Guidance delta
Management raised full-year 2026 NFFO guidance to $2.23–$2.26 per share and increased same-store NOI guidance by 100 basis points. The prior-quarter analysis reported NFFO guidance of $2.15–$2.19 per share.
Key takeaways
- Same-store NOI grew 13.8% in Q3, extending the run of double-digit growth to 11 quarters.
- Management cited $2.1 billion of year-to-date acquisitions and a $1 billion-plus pipeline, while emphasizing newer-vintage assets in affluent, supply-constrained markets.
- The quarter's revenue was above consensus, but EPS was below consensus; the reported post-event move was positive relative to the benchmark.
Management priorities
- Scale the Trilogy and SHOP platforms through operator partnerships and targeted acquisitions.
- Build data and analytics capabilities to support operator performance.
- Maintain portfolio quality through targeted acquisitions and dispositions of older, non-core assets.
Follow AHR with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$57.91Current
$28Low
$56.42Average
$70High
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Nov 7, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| UBS | Buy | Buy | Maintain | Oct 13, 2026 |
| Barclays | Overweight | Overweight | Maintain | Oct 13, 2026 |
| Scotiabank | Sector Outperform | Sector Outperform | Maintain | Sep 2, 2026 |
| Keybanc | Overweight | Overweight | Maintain | Aug 19, 2026 |
| Truist Securities | Buy | Buy | Maintain | Aug 14, 2026 |
| RBC Capital | Outperform | Outperform | Maintain | Aug 14, 2026 |
| Citigroup | Buy | Buy | Maintain | Aug 13, 2026 |
| Citizens | Market Outperform | Market Outperform | Maintain | Jul 27, 2026 |
| Morgan Stanley | Overweight | Overweight | Maintain | Nov 20, 2025 |
| JMP Securities | Market Outperform | Market Outperform | Maintain | Oct 17, 2025 |
| Citizens Capital Markets | Market Outperform | Market Outperform | Maintain | Mar 4, 2025 |
| B of A Securities | Buy | Buy | Maintain | Sep 24, 2024 |
Named analyst price targets
Upside is calculated against the persisted current price $57.91. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Raymond James | Analyst unavailable | $62 | $52.52 | +7.1% | Oct 13, 2026 |
| Barclays | Analyst unavailable | $60 | $52.52 | +3.6% | Oct 13, 2026 |
| UBS | Analyst unavailable | $65 | $54.22 | +12.2% | Sep 14, 2026 |
| Scotiabank | Nicholas Yulico | $62 | $55.83 | +7.1% | Sep 2, 2026 |
| Barclays | Richard Hightower | $66 | $55.53 | +14.0% | Aug 31, 2026 |
| KeyBanc | Analyst unavailable | $68 | $54.42 | +17.4% | Aug 19, 2026 |
| Truist Financial | Analyst unavailable | $61 | $54.14 | +5.3% | Aug 14, 2026 |
| RBC Capital | Analyst unavailable | $61 | $54.09 | +5.3% | Aug 14, 2026 |
| Compass Point | Rob Simone | $70 | $56.66 | +20.9% | Jul 21, 2026 |
| UBS | Analyst unavailable | $63 | $54.78 | +8.8% | Jul 8, 2026 |
| Barclays | Richard Hightower | $61 | $53.83 | +5.3% | Jul 7, 2026 |
| KeyBanc | Analyst unavailable | $58 | $50.46 | +0.2% | May 28, 2026 |
| RBC Capital | Michael Carroll | $56 | $50.66 | -3.3% | May 26, 2026 |
| Truist Financial | Michael Lewis | $57 | $52.13 | -1.6% | Mar 12, 2026 |
| Goldman Sachs | Analyst unavailable | $60 | $52.24 | +3.6% | Mar 2, 2026 |
| BMO Capital | Juan Sanabria | $55 | $46.33 | -5.0% | Jan 29, 2026 |
| Truist Financial | Michael Lewis | $52 | $48.01 | -10.2% | Jan 20, 2026 |
| Truist Financial | Analyst unavailable | $53 | $49.51 | -8.5% | Nov 26, 2025 |
| Morgan Stanley | Analyst unavailable | $55 | $49.56 | -5.0% | Nov 20, 2025 |
| Morgan Stanley | Ronald Kamdem | $52 | $47.87 | -10.2% | Nov 17, 2025 |
| JMP Securities | Analyst unavailable | $50 | $42.47 | -13.7% | Oct 17, 2025 |
| KeyBanc | Analyst unavailable | $43 | $41.29 | -25.7% | Oct 14, 2025 |
| UBS | Analyst unavailable | $51 | $42.49 | -11.9% | Sep 19, 2025 |
| Scotiabank | Analyst unavailable | $47 | $42.66 | -18.8% | Aug 28, 2025 |
| Truist Financial | Michael Lewis | $46 | $42.5 | -20.6% | Aug 26, 2025 |
| RBC Capital | Michael Carroll | $45 | $40.46 | -22.3% | Aug 13, 2025 |
| Jefferies | Joe Dickstein | $37 | $31.11 | -36.1% | Apr 28, 2025 |
| JMP Securities | Analyst unavailable | $35 | $30.54 | -39.6% | Mar 4, 2025 |
| Truist Financial | Michael Lewis | $29 | $26.51 | -49.9% | Nov 15, 2024 |
| Truist Financial | Michael Lewis | $27 | $25.85 | -53.4% | Sep 20, 2024 |
| KeyBanc | Austin Wurschmidt | $28 | $25.66 | -51.6% | Sep 20, 2024 |
| KeyBanc | Austin Wurschmidt | $27 | $24.58 | -53.4% | Sep 16, 2024 |
| Truist Financial | Michael Lewis | $22 | $20.93 | -62.0% | Sep 3, 2024 |
| Truist Financial | Michael Lewis | $17 | $14.61 | -70.6% | Jun 28, 2024 |
| Truist Financial | Michael Lewis | $16 | $14.1 | -72.4% | Apr 3, 2024 |
Track every rating change on AHR the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationAmerican Healthcare REIT (AHR) was forged through a significant strategic consolidation, combining Griffin-American Healthcare REIT III and Griffin-American Healthcare REIT IV, along with integrating the business and operations of American Healthcare Investors. This comprehensive merger has established AHR as a leading global real estate investment trust focused on healthcare properties, boasting an impressive portfolio with a gross investment value of approximately $4.2 billion. A core strength of the company lies in its fully integrated management platform, staffed by over one hundred highly experienced and proficient professionals. Many members of this team have a long history of collaboration, dating back to 2006, and have successfully invested in and overseen healthcare real estate assets across diverse market cycles.…
Historical context
All AHR earningsReal Estate peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| REGCO Regency Centers Corporation | FY2026 Q3 · Calendar Q4 2026 | -32.6% | +2.0% | Regency Centers Q3: Strong Leasing, Higher Guidance, and 2027 Questions |
| REG Regency Centers Corporation | FY2026 Q3 · Calendar Q4 2026 | +94.1% | -1.4% | Regency Centers Raises Outlook as Grocery-Anchored Demand Holds |
| REGCP Regency Centers Corporation | FY2026 Q3 · Calendar Q4 2026 | -32.6% | +0.6% | Regency Centers lifts outlook as occupancy and rent growth strengthen Q3 |
| CPT Camden Property Trust | FY2026 Q3 · Calendar Q4 2026 | -27.2% | -3.1% | Transcript analysis conflicts with CPT event identity |
| VMRK Vivmark Residential | FY2026 Q3 · Calendar Q4 2026 | -425.6% | +2.4% | Vivmark lifts 2026 revenue outlook as merger integration advances |
| IRM Iron Mountain Incorporated | FY2026 Q3 · Calendar Q4 2026 | +4.6% | -11.1% | Iron Mountain’s Q3 growth broadens, while expansion risks remain |
Latest beats and misses
Who reports nextBeat on EPS
- BENFY2026 Q4 · November 6, 2026+22.1% EPS+4.7% move
- PPLCFY2026 Q3 · November 6, 2026+1.7% EPS-1.2% move
- PPLFY2026 Q3 · November 6, 2026+1.7% EPS-0.6% move
- VSTFY2026 Q3 · November 6, 2026+1.0% EPS+10.6% move
- HUMFY2026 Q3 · November 6, 2026+30.0% EPS+5.3% move
- BIPFY2026 Q3 · November 6, 2026+719.8% EPS+4.3% move
Missed on EPS
- TUFY2026 Q3 · November 6, 2026-8.0% EPS-3.3% move
- PAAFY2026 Q3 · November 6, 2026-109.7% EPS-2.5% move
- CHTRFY2026 Q3 · November 6, 2026-330.3% EPS-6.2% move
- REGCOFY2026 Q3 · November 5, 2026-32.6% EPS+2.0% move
- REGCPFY2026 Q3 · November 5, 2026-32.6% EPS+0.6% move
- DKNGFY2026 Q3 · November 5, 2026-29.2% EPS-23.4% move
Get the AHR recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-11-07T16:11:01.417892+00:00
- FN2 earnings calendar · 2026-11-07T01:23:13.875996+00:00
- Polygon adjusted daily market bars · 2026-11-07T16:20:44.910791+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-11-07T16:20:44.908153+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-11-07. For educational purposes only; not investment advice.